Fmr LLC Purchases 804,963 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Fmr LLC raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 38.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,887,342 shares of the medical research company’s stock after acquiring an additional 804,963 shares during the quarter. Fmr LLC’s holdings in IQVIA were worth $684,213,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IQV. PGGM Investments increased its stake in IQVIA by 55.8% in the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after buying an additional 4,326 shares during the last quarter. Simplify Asset Management Inc. increased its position in shares of IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after acquiring an additional 3,894 shares during the last quarter. Raymond James & Associates raised its holdings in IQVIA by 0.7% during the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after acquiring an additional 5,417 shares in the last quarter. Versor Investments LP acquired a new position in IQVIA during the third quarter valued at approximately $1,328,000. Finally, Gradient Investments LLC grew its stake in IQVIA by 15.6% in the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock valued at $9,600,000 after purchasing an additional 6,134 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $201.43 on Friday. The company’s 50 day simple moving average is $219.50 and its 200 day simple moving average is $226.40. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The stock has a market capitalization of $36.56 billion, a price-to-earnings ratio of 26.43, a price-to-earnings-growth ratio of 2.10 and a beta of 1.51.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IQV. Deutsche Bank Aktiengesellschaft dropped their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Evercore ISI dropped their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday. The Goldman Sachs Group dropped their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Leerink Partners reiterated an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.